The European biotech industry association EuropaBio has named John Brennan as its new Secretary General. The life sciences expert will take over his new position in June.
In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.
Following the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer before.
AIM-listed drug discovery company e-Therapeutics plc has a new head. In early April, Raymond Barlow took over as Chief Executive Officer.
Domainex has a new Executive Chairman: Timo Veromaa has been appointed to the Board of the British drug discovery services company.
Hansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs Neurology.
Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme.
In April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest biotech industry group EuropaBio.
Cancer healthcare company Endomag, founded in 2007 as a spin-out from the University College London (UCL) and the University of Houston, has appointed Peter Keen as non-executive director. Keen will focus on supporting the company as it further extends its international reach.
?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014.